Implementation of a Provider-focused Intervention for Maximizing Human Papillomavirus (HPV) Vaccine Uptake in Young Cancer Survivors Receiving Follow-up Care in Pediatric Oncology Practices: Protocol for a Cluster-randomized Trial of the HPV PROTECT...

Overview

Journal BMC Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2022 Sep 12

PMID 36096775

Authors

Wendy Landier

Smita Bhatia

Joshua S Richman

Paula D Campos Gonzalez

Brooke Cherven

Veronica Chollette

Jamie Aye

Sharon M Castellino

Maria M Gramatges

Susan Lindemulder

Thomas B Russell

Lucie M Turcotte

Graham A Colditz

Melissa B Gilkey

James L Klosky

Affiliations

Soon will be listed here.

Abstract

Background: Childhood cancer survivors are at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent infection with the human papillomavirus (HPV). HPV vaccination is effective in preventing the infections that lead to these cancers, but HPV vaccine uptake is low among young cancer survivors. Lack of a healthcare provider recommendation is the most common reason that cancer survivors fail to initiate the HPV vaccine. Strategies that are most successful in increasing HPV vaccine uptake in the general population focus on enhancing healthcare provider skills to effectively recommend the vaccine, and reducing barriers faced by the young people and their parents in receiving the vaccine. This study will evaluate the effectiveness and implementation of an evidence-based healthcare provider-focused intervention (HPV PROTECT) adapted for use in pediatric oncology clinics, to increase HPV vaccine uptake among cancer survivors 9 to 17 years of age.

Methods: This study uses a hybrid type 1 effectiveness-implementation approach. We will test the effectiveness of the HPV PROTECT intervention using a stepped-wedge cluster-randomized trial across a multi-state sample of pediatric oncology clinics. We will evaluate implementation (provider perspectives regarding intervention feasibility, acceptability and appropriateness in the pediatric oncology setting, provider fidelity to intervention components and change in provider HPV vaccine-related knowledge and practices [e.g., providing vaccine recommendations, identifying and reducing barriers to vaccination]) using a mixed methods approach.

Discussion: This multisite trial will address important gaps in knowledge relevant to the prevention of HPV-related malignancies in young cancer survivors by testing the effectiveness of an evidence-based provider-directed intervention, adapted for the pediatric oncology setting, to increase HPV vaccine initiation in young cancer survivors receiving care in pediatric oncology clinics, and by procuring information regarding intervention delivery to inform future implementation efforts. If proven effective, HPV PROTECT will be readily disseminable for testing in the larger pediatric oncology community to increase HPV vaccine uptake in cancer survivors, facilitating protection against HPV-related morbidities for this vulnerable population.

Trial Registration: ClinicalTrials.gov Identifier: NCT04469569, prospectively registered on July 14, 2020.

Citing Articles

Pediatric Oncology Providers' HPV Vaccine Knowledge, Attitude, Self-Efficacy, and Practice after Communication Training: A Comparison with a National Survey.

Teixeira R, Grimes A, Embry L, Aguilar C, Shay L Vaccines (Basel). 2024; 12(9).

PMID: 39340090 PMC: 11435773. DOI: 10.3390/vaccines12091060.

Human Papillomavirus Vaccination in Pediatric, Adolescent, and Young Adult Cancer Survivors-Opportunity to Address Gaps in Cancer Prevention and Survivorship.

Kluczynski M, Rodriguez E, McGillicuddy C, Schlecht N Vaccines (Basel). 2024; 12(2).

PMID: 38400098 PMC: 10892003. DOI: 10.3390/vaccines12020114.

Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century.

Ehrhardt M, Krull K, Bhakta N, Liu Q, Yasui Y, Robison L Nat Rev Clin Oncol. 2023; 20(10):678-696.

PMID: 37488230 DOI: 10.1038/s41571-023-00802-w.

Examining the Barriers and Opportunities for Human Papillomavirus Vaccine Delivery in Cancer Care Settings: A Mixed-Methods Study.

Garcia M, Schlecht N, Rokitka D, Attwood K, Rodriguez E Cancer Prev Res (Phila). 2023; 16(10):581-589.

PMID: 37258419 PMC: 10810245. DOI: 10.1158/1940-6207.CAPR-23-0046.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Kempe A, Saville A, Dickinson L, Beaty B, Eisert S, Gurfinkel D . Collaborative centralized reminder/recall notification to increase immunization rates among young children: a comparative effectiveness trial. JAMA Pediatr. 2015; 169(4):365-73. DOI: 10.1001/jamapediatrics.2014.3670. View

Hofstetter A, Lappetito L, Stockwell M, Rosenthal S . Human Papillomavirus Vaccination of Adolescents with Chronic Medical Conditions: A National Survey of Pediatric Subspecialists. J Pediatr Adolesc Gynecol. 2016; 30(1):88-95. PMC: 5279719. DOI: 10.1016/j.jpag.2016.08.005. View

Malo T, Hall M, Brewer N, Lathren C, Gilkey M . Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation. Implement Sci. 2018; 13(1):57. PMC: 5907716. DOI: 10.1186/s13012-018-0743-8. View

Moss J, Reiter P, Rimer B, Brewer N . Collaborative patient-provider communication and uptake of adolescent vaccines. Soc Sci Med. 2016; 159:100-7. PMC: 4881857. DOI: 10.1016/j.socscimed.2016.04.030. View

. Overcoming Barriers to Low HPV Vaccine Uptake in the United States: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015. Public Health Rep. 2016; 131(1):17-25. PMC: 4716467. DOI: 10.1177/003335491613100106. View

Crawford N, Bines J, Royle J, Buttery J . Optimizing immunization in pediatric special risk groups. Expert Rev Vaccines. 2011; 10(2):175-86. DOI: 10.1586/erv.10.157. View

Landier W, Bhatia S, Wong F, York J, Flynn J, Henneberg H . Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. Lancet Child Adolesc Health. 2021; 6(1):38-48. PMC: 9087203. DOI: 10.1016/S2352-4642(21)00278-9. View

Dombkowski K, Harrington L, Dong S, Clark S . Seasonal influenza vaccination reminders for children with high-risk conditions: a registry-based randomized trial. Am J Prev Med. 2011; 42(1):71-5. DOI: 10.1016/j.amepre.2011.09.028. View

10.

Petrosky E, Bocchini Jr J, Hariri S, Chesson H, Curtis C, Saraiya M . Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015; 64(11):300-4. PMC: 4584883. View

11.

Wodi A, Murthy N, Bernstein H, McNally V, Cineas S, Ault K . Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(7):234-237. PMC: 8853482. DOI: 10.15585/mmwr.mm7107a2. View

12.

Castellsague X, Giuliano A, Goldstone S, Guevara A, Mogensen O, Palefsky J . Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015; 33(48):6892-901. DOI: 10.1016/j.vaccine.2015.06.088. View

13.

Melmed G, Ippoliti A, Papadakis K, Tran T, Birt J, Lee S . Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006; 101(8):1834-40. DOI: 10.1111/j.1572-0241.2006.00646.x. View

14.

Murthy N, Rodgers L, Pabst L, Parker Fiebelkorn A, Ng T . Progress in Childhood Vaccination Data in Immunization Information Systems - United States, 2013-2016. MMWR Morb Mortal Wkly Rep. 2017; 66(43):1178-1181. PMC: 5689214. DOI: 10.15585/mmwr.mm6643a4. View

15.

Brewer N, Hall M, Malo T, Gilkey M, Quinn B, Lathren C . Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial. Pediatrics. 2016; 139(1). PMC: 5192091. DOI: 10.1542/peds.2016-1764. View

16.

Gilkey M, Dayton A, Moss J, Sparks A, Grimshaw A, Bowling J . Increasing provision of adolescent vaccines in primary care: a randomized controlled trial. Pediatrics. 2014; 134(2):e346-53. PMC: 4531274. DOI: 10.1542/peds.2013-4257. View

17.

Rand C, Schaffer S, Dhepyasuwan N, Blumkin A, Albertin C, Serwint J . Provider Communication, Prompts, and Feedback to Improve HPV Vaccination Rates in Resident Clinics. Pediatrics. 2018; 141(4). PMC: 9473325. DOI: 10.1542/peds.2017-0498. View

18.

Ojha R, Jackson B, Tota J, Offutt-Powell T, Hudson M, Gurney J . Younger age distribution of cervical cancer incidence among survivors of pediatric and young adult cancers. Gynecol Oncol. 2014; 134(2):309-13. DOI: 10.1016/j.ygyno.2014.05.011. View

19.

Kessler R, Purcell E, Glasgow R, Klesges L, Benkeser R, Peek C . What does it mean to "employ" the RE-AIM model?. Eval Health Prof. 2012; 36(1):44-66. DOI: 10.1177/0163278712446066. View

20.

Zimet G, Dixon B, Xiao S, Tu W, Kulkarni A, Dugan T . Simple and Elaborated Clinician Reminder Prompts for Human Papillomavirus Vaccination: A Randomized Clinical Trial. Acad Pediatr. 2018; 18(2S):S66-S71. DOI: 10.1016/j.acap.2017.11.002. View